Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer

Rosalba Torrisi(IRCCS Humanitas Research Hospital), Marco Colleoni(European Institute of Oncology)

British Journal of Cancer

August 21, 2007

10.1038/sj.bjc.6603947

Cited by 76

Related Papers

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

|Annals of Oncology|2015|1.8k

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

|The Lancet Oncology|2016|1.8k

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

|New England Journal of Medicine|2018|1.3k

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

|Annals of Oncology|2017|1.3k

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

|New England Journal of Medicine|2019|1k